海外登壇者
| Mar. 2001 - Feb. 2005 | Resident, Department of Surgery, Asan medical center, College of Medicine, University of Ulsan, Seoul, Korea |
|---|---|
| Mar. 2005 - Feb. 2008 | Fellowship, Department of General Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea |
| Mar. 2008 - Feb. 2010 | Clinical Instructor, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea. |
| Sep. 2010 | Visiting doctor, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA / Memorial Sloan Kettering Cancer Center, New York, USA |
| Mar. 2010 - Feb. 2016 | Clinical Assistant Professor, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea |
| Mar. 2016 - Feb. 2022 | Associate Professor, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea |
| Sep. 2017 - Feb. 2019 | Visiting doctor, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA |
| Mar. 2022 – Present | Professor, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea |
Michail Ignatiadis, MD, PhD, is a medical oncologist specializing in breast cancer at the Institut Jules Bordet (IJB), Hôpital Universitaire de Bruxelles (H.U.B.) in Brussels, Belgium. He serves as the Director of the Breast Medical Oncology Clinic & Program and is a Professor of Medical Oncology. Since October 2016, he has been a member of the Executive and Research Boards of IJB and leads the Academic Trials Promoting Team (ATPT).
Since January 2021, Prof. Ignatiadis has chaired the Breast Cancer Group of the European Organisation for Research and Treatment of Cancer (EORTC). Previously, from June 2018 to January 2021, he was a member of the EORTC Board of Directors, serving as Chair of the Clinical Research Division.
Prof. Ignatiadis has played a key role in numerous investigator-initiated trials (IITs) sponsored by IJB, contributing at various stages of development. He has also served on Independent Data Monitoring Committees for international trials and has been the study chair for multiple IITs and industry-sponsored trials. His expertise in immunotherapy and blood-based biomarkers is widely recognized at the international level.
He has authored over 130 publications in peer-reviewed journals, including high-impact journals such as JAMA, Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Annals of Oncology, Lancet Oncology, JAMA Oncology, and Journal of the National Cancer Institute.
With more than two decades of experience in clinical research, leadership, and academia, Prof. Ignatiadis is a seasoned expert in the field of medical oncology
Matteo Lambertini is associate professor and consultant in medical oncology at the University of Genova – IRCCS Ospedale Policlinico San Martino in Genova (Italy).
He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research.
Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis.
He has authored more than 350 publications in peer-reviewed journals and book chapters. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy (Lambertini M et al, JAMA 2015 & Lambertini M et al, Ann Oncol 2015 & Lambertini M et al, Eur J Cancer 2017 & Lambertini M et al, J Clin Oncol 2018 & Lambertini M et al, JNCI 2022), the safety of having a pregnancy in women with prior history of breast cancer (Lambertini M et al, JNCI 2018 & Lambertini M et al, Cancer 2019 & Lambertini M et al, J Clin Oncol 2021), and the many issues in BRCA-mutated breast cancer patients (Lambertini et al, Ann Oncol 2018 & Lambertini M et al, J Clin Oncol 2020 & Lambertini M et al, JAMA 2024 & Lambertini M et al, J Clin Oncol 2025 & Blondeaux E et al, Lancet Oncol 2025).
Joana M Ribeiro is a Portuguese medical oncologist working in the Breast Unit – Department of Medical Oncology/Department of Therapeutic Innovation and Early-Stage Trials at Gustave Roussy since September 2021. She also leads the Molecular Tumor Board (RCP Moléculaire) for breast cancer.
She obtained her medical degree from the Faculdade de Medicina da Universidade de Lisboa in 2004 and started her residency in Medical Oncology in 2006 at Centro Hospitalar Universitário Lisboa Norte, becoming a board-certified medical oncologist in 2011. In the same year, she completed a fellowship at the Breast Unit of the European Institute of Oncology.
In 2012, she joined the Breast Unit of the Champalimaud Clinical Centre, where she worked until 2021. Throughout her career, she has dedicated a significant part of her activity to translational breast cancer research, with particular interests in genomics and immuno-oncology. In 2019, she completed the Global Clinical Scholars Research Training Program at Harvard University.
At Gustave Roussy, she leads the pre-operative and neoadjuvant translational trials platform in breast cancer, particularly in the field of immuno-oncology. She is Principal Investigator of the OPT-PEMBRO international academic phase III clinical trial and leads several innovative pre-operative studies, including POP-DURVA and the BIS program. She is also actively involved in molecular tumor boards and precision oncology initiatives.
She collaborates closely with the Zitvogel Laboratory, focusing on the role of the microbiome in breast cancer. She is co-investigator in several industry-sponsored and academic clinical trials.
Joana Ribeiro currently serves as a board member of the Portuguese Oncology Society (SPO) and of Portuguese reseARch group breasT caNcER (PARTNER). She is also part of the Breast Cancer Educational Committee of the European Society for Medical Oncology. She is a member of ASPIC, EACR, ESMO, and the American Society of Clinical Oncology.
Gustavo Werutsky, MD, is the Executive Director of the Latin American Cooperative Oncology Group (LACOG) and Medical Oncologist of the Breast Cancer Program, Hospital Moinhos de Vento, Porto Alegre Brazil. He serves as a member of the Breast International Group (BIG) Executive Board and is member of European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group Steering Committee. He was a former medical research fellow at the European Organization for Research and Treatment of Cancer (EORTC) 2008-2011 also a past fellow of the Flims workshop on cancer research (EORTC – NCI - AACR), Flims, Switzerland and of the ESMO translational research unit visit, Charité – Universitätsmedizin Berlin, Berlin, Germany. Graduated in Medicine at Pontifícia Universidade Católica do Rio Grande do Sul (2003), specialization in Internal Medicine (2006) and Medical Oncology (2008) at Hospital São Lucas PUCRS, Porto Alegre, Brazil and PhD (2021) in Medicine at Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil. He is member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and Sociedade Brasileira de Oncologia Clínica (SBOC). Areas of interest are breast cancer research, collaborative groups, drug development, and methods in clinical trials.
Paolo Tarantino is a breast medical oncologist and clinical researcher. Heʼs obtained his medical degree at the University Federico II of Naples (Italy) and completed his medical oncology training at the European Institute of Oncology in Milan (Italy) and University of Milan, where he also obtained a PhD in Clinical Research. In 2021 he joined the Breast Oncology Center of the Dana-Farber Cancer Institute and Harvard Medical School (Boston, MA), where he’s currently pursuing an advanced fellowship. His research focuses on the understanding of mechanisms of action of antibody-drug conjugates and development of novel predictive biomarkers. Her has published over 100 scientific articles on the topic, and he is currently contributing to multiple clinical trials and preclinical investigations to increase the precision of ADC treatment for patients with breast cancer.
2) Clinical Translational and Clinical Research Program, University of Hawai’i Cancer Center
Hideko Yamauchi, MD, FACS, is a professor in the Translational and Clinical Research program and serves as the Clinical Affairs Director at the University of Hawaii Cancer Center. She is also a professor in the Department of Surgery at the University of Hawai'i John A. Burns School of Medicine and a breast surgical oncologist at Queen’s Medical Center. After completing her initial surgical training at St. Luke’s International Hospital in Tokyo, Japan, Dr. Yamauchi conducted extensive research at the Dana-Farber Cancer Institute and the Lombardi Cancer Center at Georgetown University, focusing on developing new biomarkers for breast cancer. She completed a clinical surgical residency and fellowship at the University of Hawaii. Following her clinical training and research in the United States, she served as the director of the Breast Center at St. Luke’s International Hospital in Tokyo, Japan’s second-largest breast center, where she treated many breast cancer patients, including numerous young women. She continues her career as a physician-scientist at the University of Hawaii.
Dr. Prat is the Director of the Cancer and Blood Diseases Institute and the Director of the Clinic Comprehensive Cancer Center at Hospital Clínic of Barcelona (Spain). He is also a Professor of Medicine at the University of Barcelona (UB), and Head of the Translational Genomics and Targeted Therapies in Solid Tumors research group at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). Additionally, he serves as Director of the Breast Cancer Unit at the Barcelona Oncology Institute (IOB QuirónSalud).
In 2020, he co-founded the spin-off company Reveal Genomics, where he developed the HER2DX® genomic diagnostic test, recognized by TIME as one of the best inventions of 2022.
At the University of Barcelona, he leads the Chair of Innovation in Precision Oncology, where he also is a teacher. Throughout his career, he has gained international recognition as a prestigious oncologist and researcher for his outstanding contributions to oncology, particularly in breast cancer, genomics, biomarker development, and drug discovery. He has actively contributed to over 300 scientific publications and has supervised 10 PhD students.
Kazuaki Takabe MD, PhD, FACS, FSSO is a Professor, the Alfiero Foundation Chair and Clinical Chief of Breast Surgery at Roswell Park Comprehensive Cancer Center. He is also an Adjunct Faculty of Department of Immunology at Roswell Park, as well as a Professor of Surgery at the State University of New York - Buffalo and is an Affiliate Professor at Niigata University, Yokohama City University, Tokyo Medical University and Fukushima Medical University in Japan. He was awarded a MD at Niigata University in 1992, and PhD at Yokohama City University in 1999, and underwent postdoctoral training at the Salk Institute at La Jolla California until 2001. He underwent clinical internship at Niigata University Hospital, and completed General Surgery Residency at University of California San Diego in 2006, and Surgical Oncology Fellowship at Virginia Commonwealth University in 2008, where he stayed as a faculty and raised his rank to full Professor in both Surgery and Molecular Biology in 2016. He is in his current position since 2016. His research includes studies elucidating the clinical relevance of transcriptomic profiles of multiple types of cancer including breast cancer. He has published more than 400 peer-reviewed manuscripts to date that were cited more than 21,000 times in total (H-index of 74) according to Google Scholar. He is the Editor-in-Chief of World Journal of Oncology, Associate Editor of Journal of Surgical Research, and an Editorial Board member of Annals of Surgical Oncology. He serves as the breast service line leader who oversees the entire breast cancer care at Roswell Park that accepts over 1200 breast cancer patients new to the institution every year.
Giampaolo Bianchini is Associate Professor at Vita-Salute San Raffaele University and Head of Breast Oncology at IRCCS San Raffaele Hospital. He graduated in Medicine in 2000 from the University of Milan-Bicocca and specialized in Medical Oncology in 2004 at the University of Milan. During his training, he was a Visiting Scientist at leading US institutions, including the National Cancer Institute, MD Anderson Cancer Center, and Yale Cancer Center.
With nearly twenty-five years of clinical experience in breast cancer, Prof. Bianchini research focuses on the development of new therapeutic and immunotherapy approaches, mechanisms of resistance, and biomarker discovery to improve treatment personalization.
He has authored numerous publications in leading international journals, including Nature, The Lancet, Annals of Oncology, and Journal of Clinical Oncology, and regularly participates in major national and international conferences.
Yen-Shen Lu is currently Professor of Graduate Institute of Oncology at the National Taiwan University College of Medicine, as well as Deputy Director of Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Dr. Lu graduated from the Chinese Medical College, Taichung, Taiwan in 1992 and obtained his PhD from the National Taiwan University, Taipei, Taiwan in 2006. Dr. Lu has extensive experience as a translational researcher, clinical trial initiator, protocol writer, and as a principal investigator or co-investigator for more than 130 clinical trials. He was the co-chair of steering committee of MONALEESA-7 trial, and chair of steering committee of BYOND and RIGHT Choice trials. He is currently chair of Asian Breast Cancer Cooperative Group. He has received the Scholar in Training Award at the 92nd Annual Meeting of the American Association Cancer Research in 2001, Chien-Tien Hsu's Outstanding Cancer Research Award in 2019, and National Science and Technology Council Academic Research Award in 2020 and 2024. Dr. Lu led a series of studies focusing on young female breast cancer, regarding to the epidemiology, biology, and genetic differences between East and Western. He led a series study on the treatment of breast cancer with brain metastases, and also led studies on the new drug development of breast cancer. He is first or corresponding author of articles published in many high impact peer-reviewed international journals, including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.
2) Division of Research, Peter Mac Callum Cancer Centre
Roberto Salgado, MD, PhD: Dr. Roberto Salgado is board certified in Anatomical Pathology since 2006 and works as an Anatomic Pathologist in ZAS Hospitals, Antwerp, Belgium. He's Honorary Research Associate at the Division of Research at the Peter Mac Callum Cancer Center, Melbourne, Australia, as well as being part of the Tracer-X Consortium at the Francis Crick Institute, UK aiming at deciphering the clonal evolutional immune-pressures in lung cancer (http://tracerx.co.uk/). Currently, he's co-chairing with Sherene Loi, Peter Mac Callum Cancer Center, Melbourne, Australia, and Carsten Denkert, University of Marburg, Germany, an International Consortium of Pathologists, namely the "International Immuno-Oncology Biomarkers Working Group" (www.tilsinbreastcancer.org) that develops guidelines for the assessment of Immuno-Oncological Biomarkers in mostly breast cancer. This Working Group is a pathologist-driven group, with >900 pathologists on board, from 59 countries. This Working Group aims to develop guidelines and tools to help pathologists implement TILs in daily and clinical trial practices, including AI-TIL work in clinical trials, publishing >15 manuscripts over the past 10 years. His strategic views on Oncology have been published in major international high impact factor journals such as Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery, and Lancet Oncology. Research work has been published in Nature, The Lancet Oncology, The Lancet, Journal of Clinical Oncology, Nature Medicine. Finally, he's member of the WHO Editorial Board of the WHO Classification of Breast Tumours.
Dr. Sarat Chandarlapaty is a Professor of Medicine at Memorial Sloan Kettering with appointments as a Laboratory Head in the Human Oncology and Pathogenesis Program and Member on the Breast Medicine Service. He holds the Naddisy Foundation Endowed Chair in Breast Cancer Research. Dr. Chandarlapaty’s research has been focused on understanding the mechanisms by which breast cancers develop resistance to targeted therapy and designing novel strategies to overcome resistance. His research group discovered acquired ESR1 mutations in metastatic breast cancer and demonstrated their basis for ligand independent function and their sensitivity to novel ER antagonists. These works were foundational to the clinical development of liquid biopsies to detect ESR1 mutations in metastatic breast cancer as well as use of oral SERDs to target ER mutant breast cancers. His more recent work has defined key mechanisms of resistance to cdk4/6 inhibitors, PI3K inhibitors, and anti-HER2 therapies. His ongoing work is to develop tools and strategies to identify drug resistance earlier, and more comprehensively to generate durable treatments for patients with metastatic disease.
Professor Antoniou is a genetic epidemiologist whose work has advanced our understanding of the genetic basis of common cancers and cancer risk prediction. Through analysis of large-scale data, he has provided key robust estimates for carriers of BRCA1, BRCA2, PALB2 and other gene mutations, widely used in clinical practice. He leads the international Consortium of Modifiers of BRCA1/2 coordinating centre which showed that genetic modifiers significantly impact cancer risk for mutation carriers. He developed the BOADICEA model, which predicts breast and ovarian cancer risk using genetic and lifestyle factors, and led its implementation into the CanRisk tool (www.canrisk.org), now used globally by clinicians. He directs the Cancer Research UK, Cancer Data-Driven Detection (CD3) national strategic initiative. His contributions have been recognised with the 2019 Basser Global Prize and the 2024 Don Listwin Award.
Dr. Wonshik Han received his MD and PhD degrees from the Seoul National University (SNU) College of Medicine in Korea. He has served on the faculty at SNU since 2004 and was promoted to tenured Professor in 2015. He is the former Chief of the Breast Care Center at Seoul National University Hospital. Dr. Han currently serves as Chairman of the Board of Directors for both the Korean Breast Cancer Society (2023–2025) and the Global Breast Cancer Conference (GBCC). He is also a board member of the Korean Cancer Association and the Korea Genome Organization.
Dedicated to both patient care and research in breast cancer, Dr. Han has authored over 450 original articles in peer-reviewed journals. His research interests include breast cancer genomics, surgical techniques and their oncologic outcomes, and the development of personalized treatment strategies using novel biomarkers. He is leading several national multicenter clinical trials in South Korea, including PLATO, NAUTILUS, and NeoNAUTILUS.
Dr. Ashley Marumoto is a breast surgical oncologist at the Queen’s Medical Center in Honolulu Hawaii. She completed general surgery residency at the University of Hawaii followed by breast surgical oncology fellowship at Cedars-Sinai Medical Center in Los Angeles, California. In addition to treating patients, Dr. Marumoto teaches medical students and residents and is involved in clinical research.
Francois-Clement Bidard is a Professor of Medical Oncology at Institut Curie, in Paris, France, which is the largest center in Europe for breast cancer. He coordinates the clinical and translational research on breast cancer at Institut Curie, while his own research focuses on biomarkers to guide breast cancer therapy. His most recent achievement included designing PADA-1 and co-leading SERENA-6, which represent a new way to tackle cancer resistance to therapy. Since 2023, Prof. Bidard is also the vice-Chair of the French Breast Cancer Group UCBG.
Dr. Naoto Ueno is Director of the University of Hawaiʻi Cancer Center and a breast medical oncologist, cancer biologist, and professor of medicine. An internationally recognized physician-scientist, his work focuses on aggressive breast cancers, the tumor microenvironment, and the development of novel therapies, including antibody-drug conjugates. As a two-time cancer survivor, he brings a unique perspective as a physician, researcher, and patient. He is committed to advancing research-driven, compassionate cancer care while addressing cancer health disparities across Hawaiʻi and the U.S.-Affiliated Pacific Islands.
[Educational Background]
| 2004～2010 | Ph.D. Graduate Schools, The Catholic University of Korea, Seoul, Korea |
|---|---|
| 2001～2004 | M.S Graduate Schools, The Catholic University of Korea, Seoul, Korea |
| 1994～2000 | M.D College of Medicine, The Catholic University of Korea, Seoul, Korea |
[Work Experience]
| Fellowship: 2008～2011 | Breast Surgical Oncology, Seoul St. Maryʼs Hospital, The Catholic University of Korea, Seoul, Korea |
|---|---|
| Residency: 2001～2005 | Surgery, Catholic Medical Center, Seoul, Korea |
| Internship: 2000 ～2001 |
Seoul Red Cross Hospital, Seoul, Korea |
| 2022.2～present | Professor, Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine |
| 2019.03～2022.2 | Clinical Associate Professor, Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine |
| 2017.03～2019.01 | Associate Professor, Division of Breast Surgery, Department of Surgery, Seoul St. Maryʼs Hospital, The Catholic University of Korea, Seoul, Korea |
| 2014.03～2015.02 | Visiting Assistant Professor, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, University of Texas, Texas, U.S.A |
| 2013.03～2017.02 | Assistant Professor, Division of Breast Surgery, Department of Surgery, Seoul St. Maryʼs Hospital, The Catholic University of Korea, Seoul, Korea |
| 2011.03～2013.02 | Clinical Assistant Professor Division of Breast Surgery, Department of Surgery, Seoul St. Maryʼs Hospital, The Catholic University of Korea, Seoul, Korea |
2) Kaohsiung Medical University Hospital
■MEDICAL EDUCATION
School of Medicine: Kaohsiung Medical University Sep. 1984 ～ Jul.1991
Internship: Kaohsiung Medical University Hospital May 1990 ～ May 1991
Graduate School of Medicine: Kaohsiung Medical University Jul. 2003 ～ Jul. 2012
■ACADEMIC SERVICE
President, Taiwan Breast Cancer Society May 2025 ～ May 2028
Professor, Department of Surgery, School of Medicine Kaohsiung Medical University Feb. 2021～
Director, Taiwan Oncoplastic Breast Surgery Society Apr 2025-2028
■HOSPITAL APPOINTMENTS
Vice Superintendent, Department of Superintendent, Kaohsiung Medical University Chung-Ho Memorial Hospital Mar. 2024 ～
Education
| 2001.3 ～ 2007.2 | Medical Doctor, Yeungnam University School of Medicine |
|---|---|
| 2010.3 ～ 2016.8 | Master of Science, Sungkyunkwan University School of Medicine |
| 2017.3 ～ 2019.8 | Ph.D. in Medicine, Sungkyunkwan University School of Medicine |
Academic appointments
| 2015.5 ～ 2018.2 | Clinical Fellow, Clinical Assistant Professor, Assistant Professor, Division of Breast Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine |
|---|---|
| 2022.3 ～ present | Associate Professor, Division of Breast Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine |
Kyung-Hun Lee, M.D., Ph.D., is a Professor in the Division of Hematology and Medical Oncology at Seoul National University Hospital (SNUH) and the Seoul National University Cancer Research Institute. As a board-certified internist, he earned his medical degree and doctorate from Seoul National University.
Dr. Lee’s research and clinical expertise are centered on breast cancer, encompassing a comprehensive range of clinical trials and translational research. He is deeply involved in basic research focused on various signaling pathway inhibitors, DNA damage response (DDR) agents, antibody-drug conjugates, and the development of various breast cancer therapeutics. His work aims to bridge the gap between laboratory discoveries and clinical applications.
His professional background includes serving as a Visiting Assistant Researcher at the University of California, San Francisco (UCSF) from 2019 to 2020. Dr. Lee is also a prominent figure in the academic community, holding leadership and committee roles in several prestigious organizations.
Through his commitment to precision medicine and multidisciplinary collaboration, Dr. Lee continues to contribute to the advancement of innovative treatments and improved outcomes for breast cancer patients worldwide.
EDUCATION
2002.9 – 2008.6, Medical doctor degree, Chang Gung University, Taoyuan, Taiwan
2018.9 - Now, PhD student, Graduate Institute of Clinical Medical Science, Chang Gung University, Taoyuan, Taiwan
POSTGRADUATE TRAINING
* Surgical resident, Department of Surgery, Chang Gung Memorial Hospital, Linko, Taiwan (2009.8 - 2013.7)
* Surgical Chief Resident, Division of General Surgery, Chang Gung Memorial Hospital, Linko, Taiwan (2013.8 - 2014.7)
* Visiting clinical fellow, Department of Breast and Thyroid Surgery, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea (2018.7 – 2018.8)
EMPLOYMENT RECORD
* Attending Staff, Assistant professor, Division of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan (2014.8 - Now)
* Secretary-General, Taiwan Oncoplastic Breast Surgery Society (2017.3 – 2019.3)
* Supervisor, Taiwan Oncoplastic Breast Surgery Society (2019.3 – now)
* Vice secretary general, Taiwan Breast Cancer Society (2025.5 –)
* Founder of Breastpink
Dr. Jiun-I Lai is an Attending Physician in the Division of Medical Oncology at Taipei Veterans General Hospital and an Associate Professor at the Institute of Clinical Medicine, National Yang Ming Chiao Tung University. He received his M.D. from National Yang-Ming University and his Ph.D. in Cellular and Molecular Biology from The Scripps Research Institute, San Diego, USA. His clinical practice focuses on breast cancer and genitourinary malignancies (prostate, renal, and urothelial cancers), while his research program integrates cancer genomics, computational pathology, and translational oncology. He has authored over thirty peer-reviewed publications, including co-authorship on the phase III postMONARCH trial published in the Journal of Clinical Oncology, and previously served as Vice Secretary General of the Taiwan Breast Cancer Society (2023–2025).